当前位置:产品中心>单抗/多抗

Anti-Human PD-1 & CTLA-4 Bispecific Reference Antibody|抗人PD-1和CTLA-4双特异性参考抗体(靶标:人PD-1/CTLA-4)

货号:RB9T37015466
  • 价格:面议
  • 点击数:690
  

产品介绍

产品参数

形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号Q15116 & P16410
背景信息Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.<br>• Cancer immunotherapy using checkpoint blockade., PMID:29567705<br/>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br/>• Immune-related adverse events of checkpoint inhibitors., PMID:32382051<br/>• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br/>• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113<br/>• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885<br/>• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160<br/>• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858<br/>• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360<br/>• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704<br/>
别名Bispecific, XmAb-20717, XMAB20717, 2329669-72-7
备注For research use only. Not suitable for clinical or therapeutic use.